ArticleCancer cell international2026
Combined inhibition of PLK4 and PPM1D promotes cell death in cancer cells with 17q amplification.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPolo-like kinase 4 (PLK4) is a key regulator of centriole duplication and contributes to mitotic spindle organization during cell division. PLK4 has been implicated as pharmacological target in a subset of breast cancers and neuroblastomas harboring 17q chromosomal gains and overexpression of the E3 ubiquitin-protein ligase TRIM37. Here, we investigated factors that influence sensitivity of cancer cells to PLK4 inhibition.
methodsWe used cBio Cancer Genomics Portal and DepMap portal and performed bioinformatic analysis of copy number variations and gene expression to identify potential pharmacologically targetable genes in invasive breast carcinoma with 17q gains. Subsequently, we tested sensitivity of cancer cells to combinations of PLK4 inhibitor with other small molecule compounds and determined the impact on cell proliferation, cell death and gene expression. Validation was performed using a chemically unrelated PLK4 inhibitor, by RNAi-mediated depletion of PLK4 and in TP53 knock-out cells.
resultsWe show that sensitivity of breast cancer cells with 17q23 amplification to PLK4 inhibitor is limited by the activity of protein phosphatase PPM1D, an established negative regulator of the tumor suppressor p53. Combined inhibition of PLK4 and PPM1D stimulates the expression of p53 target genes and promotes apoptosis in breast cancer cells with 17q gains. Similarly, combined inhibition of MDM2 and PLK4 was synthetically lethal in breast cancer cells with 17q gains, whereas loss of p53 suppressed the cell death induced by PLK4 inhibition. Finally, we show that PLK4 and PPM1D or MDM2 are synthetically lethal targets in IMR-32 and CHP-134 neuroblastoma cells, confirming that targeting negative regulators of p53 enhances the efficiency of the PLK4 inhibitor in various cancers with 17q amplification.
conclusionsOur findings demonstrate that the combined inhibition of PLK4 and PPM1D or MDM2 sensitizes breast cancers and neuroblastoma with 17q gains and provide a rationale for advancing this novel drug combination into future preclinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.